Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2013

View Archived Issues

Ono obtains rights to opicapone for Parkinson's disease in Japan

Using microRNAs to differentiate between low- and high-risk pancreatic neoplasms

Roche develops interleukin-2 variant for cancer immunotherapy

Galapagos developing novel candidate drug for triple-negative breast cancer

Researchers discover novel genetic risk factor for Behcet's disease

Serum levels of beta-2-microglobulin predict mortality in patients with diabetes

New ways to protect from Parkinson's disease

SAR-154782 experiments reveal tumor growth pathways linked to NAMPT

Merck Serono obtains marketing rights to Cetrotide

Aurigene and Endo Pharmaceuticals achieve important milestones

FDA approves beta-blocker-free, fixed-combination therapy for glaucoma

Hexyon/Hexacima 6-in-1 pediatric vaccine approved in Europe

Indian scientists disclose novel CETP inhibitors

ViroPharma reports data from phase II study of VP-20621

GlaxoSmithKline presents new RORgamma modulators

MethylGene discovers novel VEGFR-2 inhibitors

Lundbeck describes new PDE10A inhibitors

Ono Pharmaceutical identifies novel S1P2 receptor antagonists

Aduro and Johns Hopkins University to evaluate Aduro vaccine technologies with anti-PD-1

ARCA biopharma and Medtronic to collaborate on atrial fibrillation burden substudy

Aastrom Biosciences commences treatment in phase IIb study of ixmyelocel-T

Synta begins treatment in confirmatory GALAXY-2 study of ganetespib

New agreement covers phase II HCV study of daclatasvir and MK-5172 combination

Senesco completes cohort 2 in phase Ib/IIa study of SNS01-T

Sareum and SRI International sign codevelopment agreement for TYK2 inhibitors

Interim phase II results for Mesoblast's mesenchymal precursor cells for intervertebral disc repair

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...